Bruker Corporation

BRKR Healthcare Medical Devices

Bruker Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.4 billion, up 2.08% from fiscal 2024.

Revenue
+1.57%
EPS
−75.4%
Free cash flow
+278.7%
Total debt
−14.7%

Quarter to September 2026, against a year earlier

61.20 3.14 +5.41%
Market cap
$8.9B
P/E
0.0×
Fwd P/E
−412×
Dividend yield
0.34%
F-score
4/9
Altman Z
2.43
Beneish M
−2.56
Dividend safety
34/100

Bruker Corporation (BRKR) P/E ratio

Alert me on P/E ratio

Bruker Corporation has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 84.5× (July 2025) — the current reading is the lowest in ten years.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 0.0× —
FY2024 77.1× 211.51%
FY2023 24.8× (28.30%)
FY2022 34.5× (24.68%)
FY2021 45.9× (12.75%)
FY2020 52.6× 31.98%
FY2019 39.8× 53.82%
FY2018 25.9× (62.50%)
FY2017 69.0× 203.93%
FY2016 22.7× (42.91%)

Quarterly newest first

Period P/E ratio Change
Sep 2026 0.0× —
Jun 2026 0.0× —
Mar 2026 0.0× —
Dec 2025 0.0× —
43 more quarters

Against its own ten years

Low 0.0× High 84.5×
Ten-year median 36.0×
Current reading's percentile 9

P/E ratio against peers

Company P/E ratio
BRKR Bruker Corporation n/m
GKOS Glaukos Corporation compare n/m
TXG 10x Genomics compare n/m
BIO Bio-Rad Laboratories, Inc. compare 9.7×
BIO.B Bio-Rad Laboratories, Inc. compare 9.9×
GMED Globus Medical, Inc. compare 19.5×
PODD Insulet Corporation compare 25.2×
SNN Smith & Nephew SNATS, Inc. compare 38.9×
PEN Penumbra, Inc. compare 80.3×
Medical Devices industry median 25.6×
Healthcare sector median 25.2×
Market median 17.9×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on BRKR